Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Glitazones associated with higher fracture rates

Rosiglitazone and pioglitazone are associated with higher fracture rates in women, a meta-analysis by UK and US researchers suggests.

Data from 10 randomised controlled trials involving 13,715 diabetes patients taking thiazolidinediones or not showed significantly reduced bone density in the lumbar spine and hip in women on the drugs.

The study reported double the risk of fractures with long-term use of thiazolidinediones in women with type 2 diabetes (OR 2.23, 95% CI 1.65–3.01; p < 0.001) but no significant increase in fracture risk in men - with an fracture estimated to occur in one out of 21 women at high risk of fracture on the drugs for one year and one fracture in every 55 in low risk women.

Canadian Medical Association Journal published online

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say